{"product_id":"krasg12v-his-tag-protein-human-ua085048","title":"KRAS(G12V) His Tag Protein, Human","description":"\u003ch4\u003eProduct Specification\u003c\/h4\u003e\u003cdiv class=\"responsive-table product-detail-table details-table\"\u003e\n\u003cbr\u003e\u003ctable style=\"width: 100%; height: auto;\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eK-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, KRAS2, RASK2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eP01116-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eAmino Acid Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003eThr2-Cys185(G12V) with His Tag at the C-Terminus\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp style=\"margin-bottom: 0px;\"\u003e20-25kDa (Reducing)\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e＞95% by SDS-PAGE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eConjugation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHis Tag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003ePhysical Appearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStorage Buffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003e50mM Tris, 200mM NaCl, 20% Glycerol, 1mM DTT, pH7.5\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStability \u0026amp; Storage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003eStable for 12 months upon stored at -80℃ from the date of receipt. And avoid repeated freeze-thaws cycles.\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eReference\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003e1.Wang X, Wang W, Zou S, Xu Z, Cao D, Zhang S, Wei M, Zhan Q, Wen C, Li F, Chen H, Fu D, Jiang L, Zhao M, Shen B. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors. Cell Res. 2024 Sep;34(9):661-664.\u003cbr\u003e2.Li D, Geng K, Hao Y, Gu J, Kumar S, Olson AT, Kuismi CC, Kim HM, Pan Y, Sherman F, Williams AM, Li Y, Li F, Chen T, Thakurdin C, Ranieri M, Meynardie M, Levin DS, Stephens J, Chafitz A, Chen J, Donald-Paladino MS, Powell JM, Zhang ZY, Chen W, Ploszaj M, Han H, Gu SS, Zhang T, Hu B, Nacev BA, Kaiza ME, Berger AH, Wang X, Li J, Sun X, Liu Y, Zhang X, Bruno TC, Gray NS, Nabet B, Wong KK, Zhang H. Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models. J Clin Invest. 2024 Dec 24;135(2):e174249.\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003c\/div\u003e\u003ch4\u003eBackground\u003c\/h4\u003e\u003cdiv\u003e\u003cp\u003e\u003cspan\u003eKRAS (Kirsten rat sarcoma viral oncogene homolog) is a small GTPase that functions as a molecular switch regulating cell proliferation, differentiation, and survival signaling. Its protein structure consists of an N-terminal catalytic G domain (containing the P-loop, switch I\/II regions, and the G12V mutation site) and a C-terminal hypervariable region (CAAX box). The G12V mutation locks the switch II region in a constitutively active GTP-bound state, abolishing GTPase activity and leading to persistent activation of downstream pathways such as RAF-MEK-ERK, PI3K-AKT, and RAL-GEF, thereby driving tumorigenesis. Clinically, KRAS G12V is one of the most common KRAS mutation subtypes in pancreatic cancer (approximately 30%), colorectal cancer, and lung cancer. Due to the lack of a cysteine residue for covalent targeting, it cannot be treated with G12C inhibitors, and therapeutic options have long been limited. In recent years, emerging strategies—including Pan-KRAS inhibitors, PROTAC degraders, mRNA vaccines targeting G12V neoantigens, and TCR-T cell therapies—have achieved breakthroughs, offering new precision treatment directions to overcome this \"undruggable\" target.\u003c\/span\u003e\u003c\/p\u003e\u003c\/div\u003e\u003ch4\u003eProtocol\u003c\/h4\u003e\u003cdiv\u003e\n\u003cp style=\"text-align:left;\"\u003e \u003c\/p\u003e\n\u003cp style=\"text-align:left;\"\u003e\u003cstrong\u003eExperimental Methods\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eExperimental Principles\u003c\/strong\u003e\u003cspan\u003e: The GTPase Glo™ assay evaluates KRAS activity by measuring the amount of GTP remaining after hydrolysis in the KRAS reaction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eExperimental Materials\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e1.\u003c\/span\u003e\u003cspan\u003eKRAS(G12V) His Tag Protein, Human\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e2.\u003c\/span\u003e\u003cspan\u003eGTPase Glo™ Assay (Promega, Catalog # V7681T)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e3.\u003c\/span\u003e\u003cspan\u003eSolid white multi-well plate (384-well plate) (Corning, Catalog #3572)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e4.\u003c\/span\u003e\u003cspan\u003ePlate Reader (PerkinElmer)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eExperimental Steps\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e1.\u003c\/span\u003e\u003cspan\u003ePrepare a 2X GTP solution containing 10 µM GTP and 2 mM DTT using GTPase\/GAP Buffer.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e2.\u003c\/span\u003e\u003cspan\u003eDilute KRAS with GTPase\/GAP Buffer to concentrations of 100 µg\/mL, 80 µg\/mL, and 60 µg\/mL, then add 5 µL to each well of a 384-well plate, respectively.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e3.\u003c\/span\u003e\u003cspan\u003eAdd 5 µL of the 2X GTP solution prepared in Step 1 to each well to initiate the reaction. Use 5 µL of GTPase\/GAP Buffer mixed with the 2X GTP solution as a blank control. The total reaction volume is 10 µL.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e4.\u003c\/span\u003e\u003cspan\u003eIncubate the reaction at room temperature (22–25°C) for 30 minutes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e5.\u003c\/span\u003e\u003cspan\u003eGently invert and mix the thawed GTPase Glo™ Reagent, 500X; do not vortex. Depending on your needs, adjust the volumes of the following components proportionally to prepare the desired volume of reconstituted GTPase Glo™.\u003c\/span\u003e\u003c\/p\u003e\n\u003cfigure class=\"table\"\u003e\u003ctable style=\"border-collapse:collapse;border:1px solid #000000;width:auto;\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eSample Name\u003c\/strong\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003eGTPase Glo ™ Reagent, 500X\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003e2 μL\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003eADP, 10 mM\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003e0.5 μL\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003eGTPase Glo™ Buffer\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003e998 μL\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003eTotal volume\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003e1 mL\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003c\/figure\u003e\u003cp\u003e\u003cbr\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e6.\u003c\/span\u003e\u003cspan\u003eAdd 10 µL of resuspended GTPase-Glo™ Reagent to the reaction system that has completed the reaction, mix briefly, and then incubate with shaking at room temperature (22–25°C) for 30 minutes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e7.\u003c\/span\u003e\u003cspan\u003eAdd 20 µL of the detection reagent, and incubate the microplate at room temperature (22–25°C) for 5–10 minutes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e8.\u003c\/span\u003e\u003cspan\u003eRead the results in endpoint mode at an emission wavelength of 555 nm (luminescence).\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"margin-right:8px;\"\u003e9.\u003c\/span\u003e\u003cspan\u003eCalculate the specific activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cfigure class=\"table\"\u003e\u003ctable border=\"1\" style=\"border-collapse:collapse;border:1px solid #000000;width:auto;\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\" style=\"text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003eSpecific Activity (pmol\/min\/μg) =\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003e(1 - Sample OD \/ BLANK OD) * 50 pmol\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd style=\"border:1px solid #000000;text-align:center;vertical-align:middle;\"\u003e\u003cp style=\"text-align:center;\"\u003e\u003cspan\u003eIncubation time (min) × amount of enzyme (μg)\u003c\/span\u003e\u003c\/p\u003e\u003c\/td\u003e\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003c\/figure\u003e\u003cp\u003e\u003cbr\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSample OD value: OD value of remaining ATP\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBlank OD value: OD value after adding GTP\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e50 pmol: Amount of GTP added\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIncubation time: 30 minutes\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eEnzyme amounts: 0.5 μg, 0.4 μg, and 0.3 μg\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"UA BIOSCIENCE","offers":[{"title":"10μg","offer_id":42989602930763,"sku":"UA085048-10μg","price":250.0,"currency_code":"USD","in_stock":true},{"title":"50μg","offer_id":42989602963531,"sku":"UA085048-50μg","price":500.0,"currency_code":"USD","in_stock":true},{"title":"100μg","offer_id":42989602996299,"sku":"UA085048-100μg","price":800.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/8375\/1499\/files\/AntBioImage_d28a9db9-3bb9-45e7-8ac4-ac2b4f4bad76.png?v=1785916877","url":"https:\/\/www.antbioinc.com\/products\/krasg12v-his-tag-protein-human-ua085048","provider":"AntBio","version":"1.0","type":"link"}